Sporanox Side Effects Center

Last updated on RxList: 4/19/2021
Sporanox Side Effects Center

Last reviewed on RxList 3/18/2019

Sporanox (itraconazole) is an antifungal agent used to treat infections caused by fungus, which can invade any part of the body including the lungs, mouth or throat, toenails, or fingernails. Sporanox is available in generic form. Common side effects of Sporanox include:

Tell your doctor if you have unlikely but serious side effects of Sporanox including:

  • signs of infection (e.g., fever, persistent sore throat),
  • trouble breathing,
  • unusual tiredness,
  • swelling ankles or feet,
  • burning/painful/frequent urination,
  • decreased sexual interest or ability,
  • hair loss,
  • muscle cramps,
  • weakness,
  • fast/irregular heartbeat,
  • mental/mood changes (e.g., depression),
  • enlarged breasts in men,
  • ringing in the ears, or
  • temporary or permanent hearing loss.

Dosage of Sporanox depends upon the condition for which it is being used to treat. Many drugs may interact with Sporanox, including blood thinners, cancer medications, cholesterol medications, cyclosporine, diabetes medication taken by mouth, antibiotics, antifungal medications, antidepressants, barbiturates, heart or blood pressure medications, HIV/AIDS medicine, sedatives, seizure medications, digoxin, disopyramide, fentanyl, isoniazid, rifabutin, rifampin, sirolimus, or tacrolimus. Tell your doctor all medications you are taking. During pregnancy, Sporanox should be used only when prescribed. It may harm a fetus. Discuss the risks with your doctor. It is recommended that men and women using this medication use two effective forms of birth control (e.g., condoms and birth control pills) while taking this medication and for 2 months after stopping it. Sporanox passes into breast milk. Consult your doctor before breastfeeding.

Our Sporanox Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Nail Disorders: What Nails Say About Your Health See Slideshow
Sporanox Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives, severe skin rash, tingling in your arms or legs; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using itraconazole and call your doctor at once if you have signs of congestive heart failure: feeling tired or short of breath, cough with mucus, fast heartbeats, swelling, rapid weight gain, or sleep problems.

Keep taking itraconazole but call your doctor at once if you have:

  • confusion, a light-headed feeling (like you might pass out);
  • blurred vision, double vision, ringing in your ears, problems with hearing;
  • fast heartbeats;
  • numbness or tingly feeling, loss of bladder control;
  • little or no urinating, pain or burning when you urinate;
  • low potassium level--leg cramps, constipation, irregular heartbeats, fluttering in your chest, increased thirst or urination, muscle weakness or limp feeling;
  • pancreatitis--severe pain in your upper stomach spreading to your back, nausea and vomiting; or
  • liver problems--nausea, upper stomach pain, tiredness, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Common side effects may include:

  • headache, dizziness, drowsiness, tiredness;
  • increased blood pressure;
  • rash, itching;
  • nausea, vomiting, stomach pain, diarrhea, constipation;
  • swelling;
  • abnormal liver function or blood tests;
  • fever, muscle or joint pain;
  • unusual or unpleasant taste in your mouth;
  • hair loss;
  • impotence, erection problems; or
  • changes in your menstrual periods.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Sporanox Professional Information


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

SPORANOX® has been associated with rare cases of serious hepatotoxicity, including liver failure and death. Some of these cases had neither pre-existing liver disease nor a serious underlying medical condition. If clinical signs or symptoms develop that are consistent with liver disease, treatment should be discontinued and liver function testing performed. The risks and benefits of SPORANOX® use should be reassessed. (see WARNINGS: Hepatic Effects and PRECAUTIONS: Hepatotoxicity and PATIENT INFORMATION.)

Adverse Events In The Treatment Of Systemic Fungal Infections

Adverse event data were derived from 602 patients treated for systemic fungal disease in U.S. clinical trials who were immunocompromised or receiving multiple concomitant medications. Treatment was discontinued in 10.5% of patients due to adverse events. The median duration before discontinuation of therapy was 81 days (range: 2 to 776 days). The table lists adverse events reported by at least 1% of patients.

Table 3: Clinical Trials of Systemic Fungal Infections: Adverse Events Occurring with an Incidence of Greater than or Equal to 1%

Body System/Adverse Event Incidence (%) (N=602)
Nausea 11
Vomiting 5
Diarrhea 3
Abdominal Pain 2
Anorexia 1
Body as a Whole  
Edema 4
Fatigue 3
Fever 3
Malaise 1
Skin and Appendages  
Rash* 9
Pruritus 3
Central/Peripheral Nervous System  
Headache 4
Dizziness 2
Libido Decreased 1
Somnolence 1
Hypertension 3
Hypokalemia 2
Urinary System  
Albuminuria 1
Liver and Biliary System  
Hepatic Function Abnormal 3
Reproductive System, Male  
Impotence 1
* Rash tends to occur more frequently in immunocompromised patients receiving immunosuppressive medications.

Adverse events infrequently reported in all studies included constipation, gastritis, depression, insomnia, tinnitus, menstrual disorder, adrenal insufficiency, gynecomastia, and male breast pain.

Adverse Events Reported In Toenail Onychomycosis Clinical Trials

Patients in these trials were on a continuous dosing regimen of 200 mg once daily for 12 consecutive weeks.

The following adverse events led to temporary or permanent discontinuation of therapy.

Table 4: Clinical Trials of Onychomycosis of the Toenail: Adverse Events Leading to Temporary or Permanent Discontinuation of Therapy

Adverse Event Incidence (%)
Itraconazole (N=112)
Elevated Liver Enzymes (greater than twice the upper limit of normal) 4
Gastrointestinal Disorders 4
Rash 3
Hypertension 2
Orthostatic Hypotension 1
Headache 1
Malaise 1
Myalgia 1
Vasculitis 1
Vertigo 1

The following adverse events occurred with an incidence of greater than or equal to 1% (N=112): headache: 10%; rhinitis: 9%; upper respiratory tract infection: 8%; sinusitis, injury: 7%; diarrhea, dyspepsia, flatulence, abdominal pain, dizziness, rash: 4%; cystitis, urinary tract infection, liver function abnormality, myalgia, nausea: 3%; appetite increased, constipation, gastritis, gastroenteritis, pharyngitis, asthenia, fever, pain, tremor, herpes zoster, abnormal dreaming: 2%.

Adverse Events Reported In Fingernail Onychomycosis Clinical Trials

Patients in these trials were on a pulse regimen consisting of two 1-week treatment periods of 200 mg twice daily, separated by a 3-week period without drug.

The following adverse events led to temporary or permanent discontinuation of therapy.

Table 5: Clinical Trials of Onychomycosis of the Fingernail: Adverse Events Leading to Temporary or Permanent Discontinuation of Therapy

Adverse Event Incidence (%) Itraconazole (N=37)
Rash/Pruritus 3
Hypertriglyceridemia 3

The following adverse events occurred with an incidence of greater than or equal to 1% (N=37): headache: 8%; pruritus, nausea, rhinitis: 5%; rash, bursitis, anxiety, depression, constipation, abdominal pain, dyspepsia, ulcerative stomatitis, gingivitis, hypertriglyceridemia, sinusitis, fatigue, malaise, pain, injury: 3%.

Adverse Events Reported From Other Clinical Trials

In addition, the following adverse drug reaction was reported in patients who participated in SPORANOX® Capsules clinical trials: Hepatobiliary Disorders: hyperbilirubinemia.

The following is a list of additional adverse drug reactions associated with itraconazole that have been reported in clinical trials of SPORANOX® Oral Solution and itraconazole IV excluding the adverse reaction term “Injection site inflammation” which is specific to the injection route of administration:

Cardiac Disorders: cardiac failure, left ventricular failure, tachycardia;

General Disorders and Administration Site Conditions: face edema, chest pain, chills;

Hepatobiliary Disorders: hepatic failure, jaundice;

Investigations: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, blood urea increased, gamma-glutamyltransferase increased, urine analysis abnormal;

Metabolism and Nutrition Disorders: hyperglycemia, hyperkalemia, hypomagnesemia;

Psychiatric Disorders: confusional state;

Renal and Urinary Disorders: renal impairment;

Respiratory, Thoracic and Mediastinal Disorders: dysphonia, cough;

Skin and Subcutaneous Tissue Disorders: rash erythematous, hyperhidrosis;

Vascular Disorders: hypotension

Post-Marketing Experience

Adverse drug reactions that have been first identified during post-marketing experience with SPORANOX® (all formulations) are listed in the table below. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.

Table 6: Postmarketing Reports of Adverse Drug Reactions

Blood and Lymphatic System Disorders: Leukopenia, neutropenia, thrombocytopenia
Immune System Disorders: Anaphylaxis; anaphylactic, anaphylactoid and allergic reactions; serum sickness; angioneurotic edema
Nervous System Disorders: Peripheral neuropathy, paresthesia, hypoesthesia, tremor
Eye Disorders: Visual disturbances, including vision blurred and diplopia
Ear and Labyrinth Disorders: Transient or permanent hearing loss
Cardiac Disorders: Congestive heart failure
Respiratory, Thoracic and Mediastinal Disorders: Pulmonary edema, dyspnea
Gastrointestinal Disorders: Pancreatitis, dysgeusia
Hepatobiliary Disorders: Serious hepatotoxicity (including some cases of fatal acute liver failure), hepatitis
Skin and Subcutaneous Tissue Disorders: Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, erythema multiforme, exfoliative dermatitis, leukocytoclastic vasculitis, alopecia, photosensitivity, urticaria
Musculoskeletal and Connective Tissue Disorders: Arthralgia
Renal and Urinary Disorders: Urinary incontinence, pollakiuria
Reproductive System and Breast Disorders: Erectile dysfunction
General Disorders and Administration Site Conditions:  
Investigations: Blood creatine phosphokinase increased

There is limited information on the use of SPORANOX® during pregnancy. Cases of congenital abnormalities including skeletal, genitourinary tract, cardiovascular and ophthalmic malformations as well as chromosomal and multiple malformations have been reported during post-marketing experience. A causal relationship with SPORANOX® has not been established. (see CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and DRUG INTERACTIONS for more information.)

Read the entire FDA prescribing information for Sporanox (Itraconazole Capsules)

© Sporanox Patient Information is supplied by Cerner Multum, Inc. and Sporanox Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors